{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T07:41:33Z","timestamp":1698824493706},"reference-count":103,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T00:00:00Z","timestamp":1274054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of newly diagnosed multiple myeloma (MM) has evolved rapidly over recent years. The availability of new effective drugs with novel mechanisms of action, such as thalidomide, lenalidomide and bortezomib in the last decade, has resulted in a new scenario expected to impact favorably on the outcome of patients with MM. The introduction of new drugs in the treatment of patients eligible for autologous stem cell transplantation (ASCT) has allowed for a significant increase of complete response rate with a positive impact on progression\u2010free survival. In patients not eligible for ASCT, randomized trials have shown that both thalidomide and bortezomib when combined with melphalan and prednisone (MP) are superior to MP and are now considered the standard of care. Ongoing trials are assessing whether MP plus lenalidomide or the combination of lenalidomide plus dexamethasone should be considered an attractive treatment option, while additional studies are needed to determine the role of routine maintenance or consolidation therapy with these new drugs. This new therapeutic armamentarium in light of adequate prophylaxis and supportive care allows clinicians to greatly improve the survival perspectives for both young and elderly patients. In this review, we report updated data for the front\u2010line therapy of MM, examining the role of new drugs either when administered as induction therapy before ASCT in younger patients or when combined with alkylating agents for the treatment of older patients. The most relevant articles on therapy of MM published from November 1982 to January 2010 (selected through PubMed), and recent meeting abstracts were used as sources for this review.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01472.x","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T16:29:07Z","timestamp":1274113747000},"page":"181-191","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs"],"prefix":"10.1111","volume":"85","author":[{"given":"Fortunato","family":"Morabito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna G.","family":"Recchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco D.","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,12]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03206.x"},{"key":"e_1_2_10_3_2","volume-title":"EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998, version 5.0","author":"Ferlay J","year":"1999"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.48.1.31"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-1-62"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8 <1588::AID-CNCR9>3.0.CO;2-G"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi235"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01082.x"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-6-687"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2004.40.1.799436"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01194.x"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00567.x"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub2"},{"key":"e_1_2_10_16_2","volume-title":"SEER Cancer Statistics Review, 1975\u20132004","author":"Ries L","year":"2007"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.171"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.159"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1411"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410"},{"key":"e_1_2_10_27_2","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood.V110.11.3597.3597","article-title":"Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but Not del17p13 in multiple myeloma: results of the Canadian MM016 trial","volume":"110","author":"Bahlis NJ","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404516"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-202010"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160090040009"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-167379"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.55.401k04_55_65"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0408"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0522"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11644"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm178"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145235"},{"key":"e_1_2_10_46_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.875"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05540.x"},{"key":"e_1_2_10_48_2","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"91","author":"Harousseau JL","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3323"},{"key":"e_1_2_10_50_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.V110.11.450.450","article-title":"Velcade\/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed patients: updated results of the IFM 2005\/01 trial","volume":"110","author":"Harousseau JL","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_51_2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood.V112.11.653.653","article-title":"First analysis of HOVON\u201065\/GMMG\u2010HD4 randomized phase III trial comparing bortezomib, Adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)","volume":"112","author":"Sonneveld P","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_52_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V114.22.351.351","article-title":"A phase III study of double autotransplantation incorporating bortezomib\u2010thalidomide\u2010dexamethasone (VTD) or thalidomide\u2010dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD","volume":"114","author":"Cavo M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06639.x"},{"key":"e_1_2_10_54_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood.V112.11.94.94","article-title":"A phase II study of bortezomib (Velcade\u00ae), cyclophosphamide (Cytoxan\u00ae), thalidomide (Thalomid\u00ae) and dexamethasone as first\u2010line therapy for multiple myeloma","volume":"112","author":"Bensinger W","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.4065\/82.10.1179"},{"key":"e_1_2_10_57_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood.V110.11.77.77","article-title":"Superiority of lenalidomide (len) plus high\u2010dose dexamethasone (HD) compared to HD alone as treatment of newly\u2010diagnosed multiple myeloma (NDMM): results of the randomized, double\u2010blinded, placebo controlled SWOG trial S0232","volume":"110","author":"Zonder JA","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404801"},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.008"},{"key":"e_1_2_10_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.8520"},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_10_63_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.V114.22.350.350","article-title":"A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versus melphalan (200 Mg\/M2) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: an interim analysis","volume":"114","author":"Palumbo A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235531"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.8520"},{"key":"e_1_2_10_66_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood.V114.22.127.127","article-title":"Novel three\u2013 and four\u2013drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi\u2010center, randomized, phase 2 evolution study","volume":"114","author":"Kumar S","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-090258"},{"key":"e_1_2_10_68_2","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1182\/blood.V114.22.2868.2868","article-title":"Clarithromycin (Biaxin)\u2010lenalidomide\u2010low\u2010dose dexamethasone (BiRd) versus lenalidomide\u2010low\u2010dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma","volume":"114","author":"Gay F","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21342"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149427"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0948"},{"key":"e_1_2_10_73_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V110.11.78.78","article-title":"Melphalan\u2010prednisone\u2010thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial","volume":"110","author":"Waage A","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_74_2","first-page":"209","article-title":"A randomised placebo controlled study with melphalan\/prednisone vs melphalan\/prednisone\/thalidomide: quality of life and toxicity","volume":"93","author":"Gulbrandsen N","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_10_75_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V112.11.649.649","article-title":"Melphalan \u2013 prednisone versus melphalan \u2013 prednisone \u2013 thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 study","volume":"112","author":"Wijermans P","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.2174\/138945009789577936"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169565"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117457"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013086"},{"key":"e_1_2_10_80_2","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood.V110.11.3593.3593","article-title":"Thalidomide combinations improve response rate: results from the MRC IX study","volume":"110","author":"Morgan GJ","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_81_2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood.V112.11.656.656","article-title":"Maintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX maintenance randomisation","volume":"112","author":"Morgan JG","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_82_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019778"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2232"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.128.128"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3463"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn197"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.17"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026548226770"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi125"},{"key":"e_1_2_10_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"e_1_2_10_93_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8573"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.02.003"},{"key":"e_1_2_10_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07495.x"},{"issue":"1","key":"e_1_2_10_97_2","first-page":"176","article-title":"Phase I\/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate\u2010 and advanced\u2010stage multiple myeloma","volume":"14","author":"Schillera GJ","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_10_98_2","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V112.11.2771.2771","article-title":"Bortezomib and dexamethasone as maintenance therapy in relapse\/refractory multiple myeloma patients","volume":"112","author":"Benevolo G","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01179.x"},{"key":"e_1_2_10_100_2","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood.V112.11.3702.3702","article-title":"Longer duration of treatment and maintenance of best response with lenalidomide and dexamethasone prolongs overall survival in patients with relapsed or refractory multiple myeloma","volume":"112","author":"San Miguel JF","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_101_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V114.22.613.613","article-title":"A phase iii study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma","volume":"114","author":"Palumbo A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7561"},{"key":"e_1_2_10_103_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood.V114.22.529.529","article-title":"Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the Intergroupe Francophone Du Myelome (IFM 2005\/02)","volume":"114","author":"Attal M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.587"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01472.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01472.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:36:33Z","timestamp":1698788193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01472.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,12]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01472.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01472.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,12]]}}}